Women's dissatisfaction with the procedure · women undergoing first trimester abortion
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nausea · women undergoing first trimester abortion
Prostaglandin alone showed no clear difference in nausea compared with combined regimen (low certainty).
1 finding from 1 review
Women's dissatisfaction with the procedure · women undergoing first trimester abortion
Prostaglandin alone showed no clear difference in women's dissatisfaction with the procedure compared with combined regimen (low certainty).
1 finding from 1 review
Blood transfusion · women undergoing first trimester abortion
Prostaglandin alone showed no clear difference in blood transfusion compared with combined regimen (low certainty).
1 finding from 1 review
Failure to achieve complete abortion · first trimester abortion
Sublingual misoprostol alone showed no clear difference in failure to achieve complete abortion compared with vaginal misoprostol alone (low certainty).
1 finding from 1 review
Nausea · first trimester abortion
Sublingual misoprostol alone showed no clear difference in nausea compared with vaginal misoprostol alone (low certainty).
1 finding from 1 review
Women's dissatisfaction with the procedure · first trimester abortion
Sublingual misoprostol alone may leads to lower women's dissatisfaction with the procedure compared with vaginal misoprostol alone (low certainty).
1 finding from 1 review
Blood transfusion · women undergoing first trimester abortion
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · first trimester abortion
It is very uncertain whether sublingual misoprostol alone changes blood transfusion compared with vaginal misoprostol alone (very low certainty).
1 finding from 1 review
Failure to achieve complete abortion · women undergoing first trimester abortion
Misoprostol 800 µg plus mifepristone 200 mg probably leads to lower failure to achieve complete abortion compared with misoprostol 400 µg plus mifepristone 200 mg (moderate certainty).
1 finding from 1 review
Nausea · women undergoing first trimester abortion
Misoprostol 800 µg plus mifepristone 200 mg showed no clear difference in nausea compared with misoprostol 400 µg plus mifepristone 200 mg (moderate certainty).
1 finding from 1 review
Women's dissatisfaction with the procedure · women undergoing first trimester abortion
Misoprostol 800 µg plus mifepristone 200 mg probably leads to lower women's dissatisfaction with the procedure compared with misoprostol 400 µg plus mifepristone 200 mg (moderate certainty).
1 finding from 1 review
Blood transfusion · women undergoing first trimester abortion
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.73 [0.63, 0.85]
Studies not reported
Moderate
Failure to maintain clinical response · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical response at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.58 [0.48, 0.71]
Studies not reported
Moderate
Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
1 finding from 1 review
RR 0.84 [0.4, 1.78]
Studies not reported
Low
Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
Aspirin showed no clear difference in graft thrombosis (28 days to 18 months) compared with placebo (low certainty).
1 finding from 1 review
Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft
1 finding from 1 review
Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found